Replies to post #354883 on Amarin Corp Plc (AMRN)

[Whalatane]

N7 / RMB. N7 thx for the link. Interesting read
Rose If Kaiser finds significant benefits in the population studied … basically ASCVD patients around 70 yrs old .. I expect them to release top line data as soon as it’s available, announce details to be presented at a later conference plus in the NEJM , and move to get all their patients that fit the trials inclusion data … on Vascepa

If data is “ mixed “ they may wait until a conference to present .

Kaiser does not make a lot of $ having their ICU’s clogged with Covid patients on O2 support
My wife worked for them
They make $ in billable procedures .. turnover of patients like CAD patients that need stents
Get them in , put in some stents , get them out … next customer please .

If MITIGATE shows benefit they will want their ASCVD patients on Vascepa ASAP

Kiwi

[rosemountbomber]

Thanks NS7, a lot of interesting reading and this one thing caught my eye (in the footnotes) that I had missed earlier:

“But Defendants' knowledge that others are using Hikma's product in an infringing way, combined with their failure to take steps to deter such use, could be relevant to their intent to encourage others' infringement. Cf. Grokster, Ltd., 545 U.S. at 939 n.12.”

[ggwpq]

Ns, thanks for posting. I am glad Judge Hall ruled for Amarin despite lackluster performance by Amarin's attorney in front of Judge Hall.